Comparative Pharmacology
Head-to-head clinical analysis: EXSERVAN versus HYDROCORTISONE AND ACETIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXSERVAN versus HYDROCORTISONE AND ACETIC ACID.
EXSERVAN vs HYDROCORTISONE AND ACETIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exservan (riluzole) is a benzothiazole derivative that modulates glutamatergic neurotransmission. Its mechanism of action involves inhibition of glutamate release, inactivation of voltage-dependent sodium channels, and interference with neurotransmitter binding to excitatory amino acid receptors.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to increased lipocortin synthesis, inhibition of phospholipase A2, decreased arachidonic acid release, and reduced prostaglandin and leukotriene production; it also suppresses cytokine expression and immune cell migration. Acetic acid is a weak acid that lowers local pH, inhibiting bacterial and fungal growth and disrupting microbial cell membranes.
Adults: 15 mg orally once daily in the morning; increase to 30 mg after 2 weeks if needed. Maximum 30 mg/day.
Instill 5 drops into affected ear(s) twice daily for 7-10 days; or as directed by physician.
None Documented
None Documented
Terminal elimination half-life is approximately 3–4 hours in patients with normal renal function; prolonged in renal impairment (up to 8–10 hours in ESRD).
Plasma t1/2: 1.5-2 hours; biological t1/2: 8-12 hours (based on HPA axis suppression).
Primarily renal excretion as unchanged drug: 80% excreted unchanged in urine; approximately 20% as metabolites; biliary/fecal <5%.
Renal: ~60-70% as metabolites; biliary/fecal: ~10-15%; unchanged drug: <5%.
Category C
Category D/X
Corticosteroid
Corticosteroid